C4 Therapeutics, Inc. (CCCC)
After hours:
Chart Events
Performance Outlook
| Previous Close | 1.8800 |
| Open | 1.8900 |
| Bid | 1.7800 x 1200 |
| Ask | 1.8100 x 1000 |
| Day's Range | 1.7850 - 1.9300 |
| 52 Week Range | 1.7850 - 10.4200 |
| Volume | |
| Avg. Volume | 1,003,079 |
| Market Cap | 89.036M |
| Beta (5Y Monthly) | 2.08 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.6300 |
| Earnings Date | Nov 01, 2023 - Nov 06, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 18.50 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for CCCC
Related Research
- C4 Therapeutics, Inc.Daily – Vickers Top Buyers & Sellers for 04/13/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.RatingFair ValueEconomic Moatlast yearArgus Research
GlobeNewswireC4 Therapeutics Announces Chief Financial Officer Succession
Kendra Adams Kendra Adams, Chief Financial Officer WATERTOWN, Mass., Sept. 05, 2023 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science to develop a new generation of small-molecule medicines and transform how disease is treated, today announced the appointment of Kendra Adams as chief financial officer (CFO), effective September 18, 2023. She will succeed Lauren White, who will be
Insider Monkey12 Best High Risk Penny Stocks to Buy Now
In this article, we will take a look at the 12 best high risk penny stocks to buy now. To see more such companies, go directly to 5 Best High Risk Penny Stocks to Buy Now. Investors are jubilant over Nvidia crushing analyst estimates in its latest quarterly report. Analysts are increasing their price targets […]
ZacksC4 Therapeutics, Inc. (CCCC) Reports Q2 Loss, Lags Revenue Estimates
C4 Therapeutics, Inc. (CCCC) delivered earnings and revenue surprises of 1.35% and 69.20%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
